Tharun is a Chartered Financial Analyst from the CFA Institute, U.S. A graduate from Loyola College, Chennai, he started his career in Goldman Sachs at their Bangalore office. Prior to his current role at Proactive Investors, he worked as an equity analyst at a global research and analytics company in Mumbai, assisting institutional clients across Asia.
Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084.
The agreement supports Zelda’s path to rapid commercialisation through the development of clinically validated cannabis medicines.
MMJ is a global cannabis investment company with a portfolio of listed and unlisted holdings.
CBRE made a £267mln takeover bid for Telford Homes earlier this week as part of its plan to enter the UK’s growing build-to-rent market. But what exactly is build-to-rent?
The Australian bio-pharmaceutical company is developing proprietary cannabinoid formulations to treat a variety of medical conditions.
1,000 patients have now been prescribed Althea medicinal cannabis products in Australia.
An Australian fund manager has increased its stake to 19.61% in the company.
Construction has commenced on Australia’s first salt-lake brine SOP production operation.